All In Biotech

Investigational drug · Phase 3

Cetrelimab

Also called: JNJ-63723283

Not approved by FDA. In 8 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Urinary Bladder Neoplasms, Carcinoma, Non-Small-Cell Lung, Neoplasms.

Phase 3

Last checked: Nov 19, 2026Latest source record: Nov 17, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations

Highest phase

Phase 3

Industry-sponsored trials

Phase 2 and 3 trials

8

7 still active

All registered trials

20

Any phase or sponsor naming "Cetrelimab"

First trial start

2016

Nov 21, 2016

Sponsors

Lead sponsors of its Phase 2 and 3 trials.

All registered trials by phase

Every ClinicalTrials.gov drug study naming "Cetrelimab", any sponsor or status.

Conditions studied

As listed on its trial records.

  • Urinary Bladder Neoplasms
  • Carcinoma, Non-Small-Cell Lung
  • Neoplasms
  • Urothelial Carcinoma
  • Prostatic Neoplasms, Castration-Resistant
  • Bladder Cancer

Approved drugs for the same conditions: Bladder and urothelial cancer · Oncology · Kidney and urology

Largest trials

Live from ClinicalTrials.gov: studies naming "Cetrelimab" as an intervention, largest first.

All trials

Newest research

PubMed records naming it or its code names, newest first.

All 19 on PubMed

Also in development for Urinary Bladder Neoplasms

  • Intismeran autogeneV940, mRNA-4157Phase 310 trials

    Merck & Co. · Non-small Cell Lung Cancer, Melanoma, Bladder Cancer

  • TAR-200JNJ-17000139, Gemcitabine-Releasing Intravesical SystemPhase 35 trials

    Johnson & Johnson (Janssen) · Urinary Bladder Neoplasms, Non-Muscle Invasive Bladder Neoplasms, Bladder Cancer

  • VepugratinibLY3866288Phase 32 trials

    Eli Lilly · Urinary Bladder Neoplasms, Urologic Neoplasms, Receptor, Fibroblast Growth Factor, Type 3

  • MK-3120SKB410Phase 24 trials

    Merck & Co. · Bladder Cancer, Advanced Solid Tumors, Malignant Neoplasm

Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do. More from Johnson & Johnson (Janssen).

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.